my.jhsph.eduBloomberg School of Public Health HomeDEPARTMENTSACADEMICSRESOURCESRESEARCH & CENTERSADMISSIONS
Public Health News
NEWS CENTER

Home

Terrorism and Public Health Preparedness

News Archives

SUBSCRIPTIONS

RSS/Podcasts 
Magazine 
Email Updates
 
Media Archive

MEDIA INQUIRIES

Media Services

410-955-6878

paffairs@jhsph.edu

HIGHLIGHTS

School at a Glance 

Dean's Letter

Accreditation

Scholars

Lectureships

Student Webpages

Honors & Awards

PUBLICATIONS

Saving Lives Millions at a Time

Johns Hopkins Public Health Magazine



View Contents

Johns Hopkins Public Health Magazine

View Contents

View Contents



Learn About Our Global Projects
Learn About Our Global Projects

Learn About Our Global Projects



 email to a colleague | support our research 

September 22, 1999

Frequent Injection Drug Use May Increase Risk

The number of different viral species in frequent injection drug users (IDUs) may be more than 60 percent higher than in non-users. Researchers found a direct correlation between how frequently an IDU injects drugs and the number of different varieties of HIV that exist within that drug user. The study, which appeared in the October 1999 issue of The Journal of Infectious Diseases, found that frequent injection drug use may provide a more fertile environment for the emergence of resistance to antiretroviral therapy, the drug treatment used to slow or suppress the progression of the HIV virus.

Richard B. Markham, MD, associate professor, Molecular Microbiology and Immunology, Johns Hopkins School of Public Health, said, "When there are a myriad of genetic mutations of the HIV virus inside the host, there is always the possibility that one of those mutations will cause resistance to drug therapy. It is a numbers game. Any activity that causes additional genetic mutations will increase the chances for appearance of those mutations that enable the virus to resist antiretroviral therapy."

Previous studies, performed before the availability of highly active antiretroviral therapy, have shown the course of HIV infection to be similar between IDUs and non-users, indicating that host factors controlling HIV infection were essentially equivalent between the two groups. However, the current study raises concerns that, when the host environment is changed by the addition of antiretroviral therapy, frequent drug users may be at a disadvantage. This study demonstrates the importance of reducing injection drug use in individuals being treated with antiretroviral agents. Treated individuals who continue to inject frequently should be monitored closely for the emergence of drug resistance.

This study was funded by a grant from the National Institutes of Health.

Public Affairs Media Contacts for the Johns Hopkins Bloomberg School of Public Health: Tim Parsons or Kenna Brigham @ 410-955-6878 or paffairs@jhsph.edu.

TOOLS

Contact JHSPH
Feedback
Email this Page
Course Search
Faculty Directory
Find an Expert
CoursePlus

Make a Gift

SEARCH
LEARN MORE ABOUT
Malaria

Online: "Progress Against Malaria"

"Breaking the Cycle" Special Report

Malaria Research Institute

Pandemic Flu

Pandemic Flu Guide for Individuals and Families

FAQ

Water

The Future of Drinking Water: Making it Safe

Email Hoax About Freezing Water Bottles



Johns Hopkins University

  © 2008, Johns Hopkins University. All rights reserved.
 Web policies, 615 N. Wolfe Street, Baltimore, MD 21205, 410-955-6878